Symptoms

Chemotherapy-induced peripheral neuropathy

Bryan Schneider, Dawn L. Hershman, Charles Loprinzi

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a problematic, treatment-induced toxicity that has the potential to impact quality of life and limit the doses of curative intent therapy. This therapy-induced side effect is one of the most troublesome in oncology clinical practices, considering the morbidity, the frequency, and the potential irreversibility of this problem. Patients with breast cancer are particularly impacted by this side effect as multiple agents commonly used for this disease can cause neuropathy. In this chapter, we provide an overview of CIPN, including: clinical predictors, frequency, and its impact on quality of life. Further, we highlight the pathophysiology and review the literature to date for agents designed to prevent or treat CIPN. We also highlight the most important ongoing clinical and translational research questions that hope to help better predict and prevent this toxicity. This includes optimizing the methods of assessment, using host specifi c factors (Race and genetics) to predict those more likely to experience CIPN, and determining how CIPN might impact clinical decisions toward therapy.

Original languageEnglish (US)
Pages (from-to)77-87
Number of pages11
JournalAdvances in Experimental Medicine and Biology
Volume862
DOIs
StatePublished - 2015

Fingerprint

Chemotherapy
Peripheral Nervous System Diseases
Drug Therapy
Toxicity
Quality of Life
Translational Medical Research
Oncology
Medical Oncology
Therapeutics
Breast Neoplasms
Morbidity

Keywords

  • Breast cancer
  • CIPN (Chemotherapy-induced peripheral neuropathy)
  • Neuropathy
  • Pharmacogenetics
  • PRO (Patient reported outcomes)
  • Taxanes
  • Toxicity

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Symptoms : Chemotherapy-induced peripheral neuropathy. / Schneider, Bryan; Hershman, Dawn L.; Loprinzi, Charles.

In: Advances in Experimental Medicine and Biology, Vol. 862, 2015, p. 77-87.

Research output: Contribution to journalArticle

Schneider, Bryan ; Hershman, Dawn L. ; Loprinzi, Charles. / Symptoms : Chemotherapy-induced peripheral neuropathy. In: Advances in Experimental Medicine and Biology. 2015 ; Vol. 862. pp. 77-87.
@article{794db303612148759853f56666b4de6a,
title = "Symptoms: Chemotherapy-induced peripheral neuropathy",
abstract = "Chemotherapy-induced peripheral neuropathy (CIPN) is a problematic, treatment-induced toxicity that has the potential to impact quality of life and limit the doses of curative intent therapy. This therapy-induced side effect is one of the most troublesome in oncology clinical practices, considering the morbidity, the frequency, and the potential irreversibility of this problem. Patients with breast cancer are particularly impacted by this side effect as multiple agents commonly used for this disease can cause neuropathy. In this chapter, we provide an overview of CIPN, including: clinical predictors, frequency, and its impact on quality of life. Further, we highlight the pathophysiology and review the literature to date for agents designed to prevent or treat CIPN. We also highlight the most important ongoing clinical and translational research questions that hope to help better predict and prevent this toxicity. This includes optimizing the methods of assessment, using host specifi c factors (Race and genetics) to predict those more likely to experience CIPN, and determining how CIPN might impact clinical decisions toward therapy.",
keywords = "Breast cancer, CIPN (Chemotherapy-induced peripheral neuropathy), Neuropathy, Pharmacogenetics, PRO (Patient reported outcomes), Taxanes, Toxicity",
author = "Bryan Schneider and Hershman, {Dawn L.} and Charles Loprinzi",
year = "2015",
doi = "10.1007/978-3-319-16366-6_6",
language = "English (US)",
volume = "862",
pages = "77--87",
journal = "Advances in Experimental Medicine and Biology",
issn = "0065-2598",
publisher = "Springer New York",

}

TY - JOUR

T1 - Symptoms

T2 - Chemotherapy-induced peripheral neuropathy

AU - Schneider, Bryan

AU - Hershman, Dawn L.

AU - Loprinzi, Charles

PY - 2015

Y1 - 2015

N2 - Chemotherapy-induced peripheral neuropathy (CIPN) is a problematic, treatment-induced toxicity that has the potential to impact quality of life and limit the doses of curative intent therapy. This therapy-induced side effect is one of the most troublesome in oncology clinical practices, considering the morbidity, the frequency, and the potential irreversibility of this problem. Patients with breast cancer are particularly impacted by this side effect as multiple agents commonly used for this disease can cause neuropathy. In this chapter, we provide an overview of CIPN, including: clinical predictors, frequency, and its impact on quality of life. Further, we highlight the pathophysiology and review the literature to date for agents designed to prevent or treat CIPN. We also highlight the most important ongoing clinical and translational research questions that hope to help better predict and prevent this toxicity. This includes optimizing the methods of assessment, using host specifi c factors (Race and genetics) to predict those more likely to experience CIPN, and determining how CIPN might impact clinical decisions toward therapy.

AB - Chemotherapy-induced peripheral neuropathy (CIPN) is a problematic, treatment-induced toxicity that has the potential to impact quality of life and limit the doses of curative intent therapy. This therapy-induced side effect is one of the most troublesome in oncology clinical practices, considering the morbidity, the frequency, and the potential irreversibility of this problem. Patients with breast cancer are particularly impacted by this side effect as multiple agents commonly used for this disease can cause neuropathy. In this chapter, we provide an overview of CIPN, including: clinical predictors, frequency, and its impact on quality of life. Further, we highlight the pathophysiology and review the literature to date for agents designed to prevent or treat CIPN. We also highlight the most important ongoing clinical and translational research questions that hope to help better predict and prevent this toxicity. This includes optimizing the methods of assessment, using host specifi c factors (Race and genetics) to predict those more likely to experience CIPN, and determining how CIPN might impact clinical decisions toward therapy.

KW - Breast cancer

KW - CIPN (Chemotherapy-induced peripheral neuropathy)

KW - Neuropathy

KW - Pharmacogenetics

KW - PRO (Patient reported outcomes)

KW - Taxanes

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=84931282163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931282163&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-16366-6_6

DO - 10.1007/978-3-319-16366-6_6

M3 - Article

VL - 862

SP - 77

EP - 87

JO - Advances in Experimental Medicine and Biology

JF - Advances in Experimental Medicine and Biology

SN - 0065-2598

ER -